Dr. Mehmet Oz discussed Medicaid reform, Medicare upcoding, and timely FDA drug reimbursements in his Senate confirmation hearing. Read more here.

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts said.

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

A European business lobby group urged China to take steps not to prioritise low prices over product safety in the country's ...

A federal judge on Thursday ordered six federal agencies to rehire thousands of workers with probationary status who had been ...

Ahead of Dr. Oz’s confirmation hearing to become administrator of CMS, Senator Warren urges him to divest ties to healthcare ...

Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Endo and Mallinckrodt, two drugmakers seeking to recover from opioid lawsuits and bankruptcies, are betting a combination will help. Investors took a dim v ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.